Dental Plaque – Talk Bio

Actionable Insights Powered by AI

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

3 days ago talkbio0Tagged ARIA risk, Binding action, Biological Markers, clinical outcomes, Dental Plaque, oligomer selectivity, Phase 1b Trial, PMN310, PRECISE-AD trial, ProMIS Neurosciences, Toxic Oligomers, vascular deposit binding

ProMIS Neurosciences; PMN310; toxic oligomers; ARIA risk; PRECISE-AD trial; peer-reviewed publication; oligomer selectivity; plaque binding; vascular deposit binding; phase 1b trial; biomarkers; clinical outcomes

J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

3 months ago talkbio0Tagged Dental Plaque, deucravacitinib, IL-23 receptor antagonist, JNJ-2113, Johnson & Johnson, Myers, oral peptide, Phase 3 clinical trial, Psoriasis, skin clearance, Sotyktu

Icotrokinra; JNJ-2113; Johnson & Johnson; IL-23 receptor antagonist; Sotyktu; deucravacitinib; plaque psoriasis; Phase 3 clinical trial; skin clearance; oral peptide; Bristol Myers Squibb

J&J’s Icotrokinra (JNJ-2113) Achieves Significant Success in Phase 3 Trials for Moderate to Severe Plaque Psoriasis

1 year ago talkbio0Tagged Clinical Trials, Dental Plaque, IL-23 receptor antagonist, JNJ-2113, Phase, Protagonist Therapeutics, Psoriasis

JNJ-2113, icotrokinra, IL-23 receptor antagonist, plaque psoriasis, Phase 3 clinical trials, Johnson & Johnson, Protagonist Therapeutics

Skyrizi Surpasses Humira as AbbVie’s Top-Selling Drug

1 year ago talkbio0Tagged AbbVie, Arthritis, Psoriatic, Crohn 's disease, Dental Plaque, Humira, Immunology, Psoriasis, Skyrizi

Skyrizi, Humira, AbbVie, revenue leader, immunology, plaque psoriasis, psoriatic arthritis, Crohn’s disease

Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis

1 year ago talkbio0Tagged acceptance, Chinese Language, Clinical Trials, Dental Plaque, inhibitors, Innovent, interleukin-23, NDA, Phase 3, Phase 3, picankibart, Regulators (device)

Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance

Organon Expands Dermatology Portfolio with $1.2B Acquisition of Dermavant and VTAMA Cream

1 year ago talkbio0Tagged Acquisition (action), Dairy Cream, Dental Plaque, Dermatitis, Atopic, Dermatology field, Dermavant, Organon, Psoriasis, steroid-free skin cream, Vtama

Organon, Dermavant, VTAMA cream, dermatology, acquisition, steroid-free skin cream, plaque psoriasis, atopic dermatitis

Organon Expands Dermatology Portfolio with Acquisition of Dermavant for Up to $1.2 Billion

1 year ago talkbio0Tagged Acquisition (action), Dairy Cream, Dental Plaque, Dermatitis, Atopic, Dermatology field, Dermavant, Organon, Psoriasis, Roivant, tapinarof, Vtama

Organon, Dermavant, Roivant, dermatology, VTAMA cream, tapinarof, plaque psoriasis, atopic dermatitis, acquisition

Alumis Completes IPO, Raising $250 Million for Inflammation and Immunology Research

1 year ago talkbio0Tagged Alumis, biotech, Dental Plaque, Immunology, Inflammation, Inhibitor, IPO, Psoriasis, TYK2 gene, Uveitis

Alumis, IPO, Inflammation, Immunology, Biotech, TYK2 Inhibitor, Plaque Psoriasis, Uveitis, Lupus

Innovent to Submit IL-23 Psoriasis Drug to Chinese Regulators Following Phase 3 Success

2 years ago talkbio0Tagged China, CLEAR-1, Clinical Research, Dental Plaque, Innovent, interleukin-23, picankibart, Psoriasis, regulatory

Innovent, IL-23, psoriasis, picankibart, phase 3, China, regulatory submission, plaque psoriasis, CLEAR-1 study